Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.20, $0.05 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $202.12 million versus the consensus estimate of $249.52 million.

GUIDANCE:

Corcept Therapeutics sees FY2026 revenue of $0.9-1 billion, versus the consensus of $0.96 billion.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.